NHS AAA Screening Programme Data Linkage With HES and ONS Datasets
NCT ID: NCT03407664
Last Updated: 2020-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000000 participants
OBSERVATIONAL
2020-07-01
2021-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In England this evidence is based on a randomised trial data from the late nineties, however, since these data were published the number of men identified with AAA has fallen to a current prevalence of just over 1%. Furthermore, similarly designed randomised trials in Western Australia demonstrated no meaningful differences in AAA or cardiovascular deaths. The first aim of our research is to follow men who have been screened for AAA in England in order to establish the medium (5 years) and long term (10+ years) impact of AAA screening on the risk of a AAA, cardiovascular and all-cause morbidity/mortality in a non-trial setting. Men with sub-aneurysms will be examined (Aorta=2.5-2.9cm) as several studies suggest this group is at risk of late rupture.
The role of patient pathways to improve uptake of the screening programme will be examined. Current data suggests that the most 'deprived' men in England are the least likely to turn up for screening but the most likely to have an abdominal aneurysm. Outcomes in this group will be analysed including the benefit of a new patient pathway to improve uptake nationally.
Lastly, several large studies have demonstrated that a larger aortic diameter may be associated with cardiovascular risk. The addition of aortic diameter to current risk prediction models could improve the accuracy of these models and will be examined.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety of Targeted AAA Screening
NCT03365050
Female Aneurysm Screening STudy
NCT03277781
Detecting Abdominal Aortic Aneurysms in First Degree Relatives (Adult Offsprings) to AAA Patients (DAAAD)
NCT04623268
Screening for Abdominal Aortic Aneurysms in the General Practice by Ultraportable Ultrasound
NCT05617326
Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey
NCT01390740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The incidence of AAA is falling in western populations likely secondary to a reduction in the number of individuals smoking cigarettes in addition to other pharmacological (increase in the use of anti-platelets and statins) and lifestyle (exercise) modifications. This reduction in the number of men with AAA raises the question of whether in the long term community AAA screening will remain cost effective, however, to examine cost effectiveness it is important to establish what happens to all men invited to AAA screening over time. One aspect of this is examining the long term outcomes of men who have an aortic diameter above 3.0cm whilst another highly debated topic is the outcome of men with an aortic diameter between 2.5-2.9cm which may be defined as sub-aneurysmal. This group of men have been demonstrated to be at risk of developing AAA in later life (over 10 years) and there is a risk that these discharged men later go on to be at risk of aneurysm rupture.
the study would also like to examine the impact of deprivation on uptake of the screening programme is England. Uptake of the screening programme in 2015-2016 was 85.4%, however this varies from 76.6% in Merseyside to 92.0% in less deprived parts of England. Previous studies have highlighted the association between social deprivation and poor uptake and pilot data from our study suggests that this deprived group are also more likely to have an abdominal aneurysm. This puts this group at great risk without the benefit of screening to prevent rupture. Within this study outcomes in this group (AAA related death, admission and all-cause mortality/morbidity) will be assessed in order to accurately assess the cost benefit of new patient pathways to improve AAA screening uptake in the most deprived group.
Lastly, over time NAAASP will detect a large number of patients with small aneurysms that will require regular surveillance. Patients with AAA are widely recognized to be at a higher cardiovascular risk then the general population for example one recent systematic review identified a strong link between cardiovascular death and time from diagnosis of small AAA with a 3% increased risk of cardiovascular mortality per year compared with the general population. Duncan and Colleagues also described long term outcomes of men screened for AAA in Scotland finding that the most common cause of death in those with AAA was cardiovascular disease and that this risk increases with aortic diameter. Increasing aortic diameter and poor cardiovascular outcomes have also been noted in several other large cohort studies.
Aortic Diameter may be an independent marker of cardiovascular risk that could improve the sensitivity of current cardiovascular risk prediction models used commonly in England. Screening may also be an opportunity to identify men at higher cardiovascular risk (both with an aneurysm and without) creating added benefit to the screening programme. None the less contemporary data suggests that cardiovascular risk is inadequately addressed in this high risk cohort and requires further study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Men Screened for AAA in England
Men invited into the NHS AAA Screening programme in England in the years 2013-2017.
this field is not applicable
We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
this field is not applicable
We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged 65 years of age at the time of their invitation to the NHS AAA screening programme
3. All men who have consented for their data to be used for the purposes of research
Exclusion Criteria
65 Years
65 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Leicester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Leicester
Leicester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0652
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.